Select region

With critically ill patients, there’s no time for delay.  

Cardiogenic shock, acute respiratory distress syndrome, septic shock or pulmonary embolisms are conditions that can become life-threatening. Patients with severe cardiac and/or pulmonary failure require immediate support to maintain gas exchange and end-organ perfusion.

Extracorporeal Membrane Oxygenation (ECMO) provides clinicians a powerful option to help stabilize blood circulation and/or respiratory functions of affected patients. [1]

ECMO can provide time for the clinician to treat the underlying cause.

Gain time for life with Getinge ECMO solutions.

Gain time to recover

How can Extracorporeal Membrane Oxygenation (ECMO) help your patients?

For critically ill patients, time is precious. ECMO buys additional time, supporting organ perfusion, while the patient heals or further treatments are applied. This gives caregivers more time to optimize the patient's therapy while easing the body’s workload.

ECMO can be used for a wide range of indications in intensive care, emergency medicine, cardiology, cardiac surgery, and patient transport.

Clinicians trust Getinge’s knowledge and experience

Getinge ECMO systems are small and lightweight heart-lung support systems. Although Extracorporeal Membrane Oxygenation (ECMO) is not a therapy itself, it acts as a bridge to further treatment, recovery or transplantation. This gives caregivers more time to optimize the patient's therapy while easing the body’s workload. 

Getinge ECMO systems are intended for intra-hospital and some also for inter-hospital patient transport. Even during transport, the portable systems allow adequate oxygenation of the patient and CO2 reduction to optimize organ perfusion.

Application areas and indications

ECMO offers a bridge to therapy for patients with a variety of medical conditions, including respiratory failure, ARDS, pulmonary embolism, cardiogenic shock, cardiac arrest, failure to wean from bypass after cardiac surgery, or as a bridge to transplantation or placement of a ventricular assist device.


Cardiac Applications

ECMO and Cardiogenic Shock

ECMO has become a life-saving tool to support patients with severe and refractory cardiogenic shock, either after myocardial infarction, cardiac surgery, myocarditis or intoxication.

eCPR and Cardiac Arrest

Annually, there are millions of cardiac arrest events all with low percent survival. Recent randomized controlled trials [2],[3] suggest extracorporeal cardiopulmonary resuscitation (eCPR) may provide a survival benefit in carefully selected patients with cardiac arrest.

Respiratory Applications

ECMO and Covid-19

Getinge ECMO solutions provide a resource for the care of patients with COVID-19, offering time for their damaged lungs to recover when mechanical ventilation is not enough.


Veno-Venous Extracorporeal Membrane Oxygenation (VV ECMO) solutions can be a resource for the care of patients with severe Acute Respiratory Distress Syndrome (ARDS).


ECCO₂R and Respiratory Medicine

Extracorporeal Carbon Dioxide Removal (ECCO₂R) removes carbon dioxide (CO₂) from the blood using an extracorporeal circuit which facilitates the protection and recovery of the lungs.

Explore the ECMO product offering

Getinge offers a broad, high-end product portfolio for short-term or prolonged Extracorporeal Membrane Oxygenation (ECMO). It includes a choice of devices and consumables to provide individual extracorporeal heart and/or lung support, such as centrifugal pumps, oxygenators, heater units, tubing sets, catheters and cannulae.

  1. 1. Extracorporeal Life Support Organization (ELSO); General Guidelines for all ECLS Cases; August, 2017

  2. 2. Effect of Intra-arrest Transport, Extracorporeal Cardiopulmonary Resuscitation, and Immediate Invasive Assessment and Treatment on Functional Neurologic Outcome in Refractory Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial
    Randomized Controlled Trial JAMA. 2022 Feb 22;327(8):737-747. doi: 10.1001/jama.2022.1025.

    Prague OHCA
  3. 3. The ARREST trial Yannopoulos D, Bartos J, Raveendran G, Walser E, et al. Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial. Lancet. 2020 Nov 12:S0140-6736(20)32338-2. doi: 10.1016/S0140-6736(20)32338-2. Epub ahead of print. PMID: 33197396 NCT03880565

    The ARREST trial – ECMO CPR
  4. 4. HLS Set Advanced in combination with HLS Cannulae with Bioline Coating can be used for up to 30 days in CE region.